GlassScriptPhysician profile
Peter P Scalise
NPI 1356330955
$3,499.76
in general payments reported to CMS, 2019-2025
26 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $45.30 · 2021: $65.39 · 2022: $1,358 · 2023: $288 · 2024: $597 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $686.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $434.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $276.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $272.55 | 2022-2024 | Verquvo |
| Pfizer INC. | $238.74 | 2022-2025 | |
| Novo Nordisk INC | $180.77 | 2024-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.16 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.71 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $115.14 | 2021-2024 | Farxiga |
| Amgen INC. | $113.13 | 2022-2024 | Repatha |
| Cvrx, INC. | $111.86 | 2022 | |
| Astellas Pharma US INC | $102.02 | 2019 | |
| Penumbra, INC. | $95.60 | 2025 | Indigo System |
| Shockwave Medical, INC | $86.58 | 2024-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Medtronic, INC. | $83.40 | 2024-2025 | Venaseal, Mosaic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $77.04 | 2023-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $63.45 | 2022-2025 | Synergy |
| Abiomed | $59.50 | 2024 | Impella |
| Irhythm Technologies, INC. | $56.27 | 2022-2023 | Zio Xt Patch |
| Actelion Pharmaceuticals US, INC. | $38.35 | 2022-2023 | Opsumit |
| Scpharmaceuticals INC. | $34.59 | 2024 | |
| Inspire Medical Systems, INC. | $24.06 | 2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $18.69 | 2024 | Arcalyst |
| Terumo Medical Corporation | $16.09 | 2019 | |
| Elutia, INC. | $13.80 | 2025 | Ecm Patch,Pouch |
| Ethicon US, LLC | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Scalise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.